Nilörngruppen AB
27.7.2026 16:45:00 CEST | Globenewswire | Press release
Nilörngruppen’s delisting application approved – last day of trading will be 10 August 2026
Nilörngruppen’s delisting application approved – last day of trading will be 10 August 2026
As previously announced, Nilörngruppen AB (publ) ("Nilörngruppen") has applied for delisting of the Nilörngruppen B-share from Nasdaq Stockholm in the light of Trimco Group (UK) Limited owning over 90 percent of the shares and votes in Nilörngruppen.
Nasdaq Stockholm has today approved Nilörngruppen’s application for delisting and decided that the last day of trading will be 10 August 2026.
Contact
Krister Magnusson
CEO
krister.magnusson@nilorn.com
+46 704–852 114
General information about Nilörngruppen
Nilörngruppen is a global company, founded in the 1970s, with expertise in adding value to brands through branding and design in the form of labels, packaging and accessories, primarily for customers in the fashion and apparel industry. Nilörngruppen offers complete, creative and customised solutions within branding, design, product development and logistics services. The Group operates through its own companies in Sweden, Denmark, the United Kingdom, Germany, Belgium, Portugal, Hong Kong, India, Turkey, China, Bangladesh, Italy, Switzerland, Vietnam, the United States, Pakistan, Sri Lanka and the Netherlands. For more information, please visit: www.nilorn.se
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FireFly Metals Limited25.8.2026 02:49:03 CEST | Press release
Investor Presentation: Green Bay Preliminary Economic Assessment and Capital Raising
FireFly Metals Limited25.8.2026 02:44:28 CEST | Press release
Economic study demonstrates scale, grade, long life, growth potential and robust financial returns
Royal Philips24.8.2026 23:04:56 CEST | Press release
Philips prices EU green bond for EUR 650M
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom